An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
This study surveyed US adolescent residential addiction treatment facilities to assess treatments used for adolescents younger than 18 years seeking treatment for opioid use disorder.
Conflict of Interest Disclosures: Dr Hadland reported receiving grants from the National Institute on Drug Abuse/National Institutes of Health and the Centers for Disease Control and Prevention and consulting agreements with Boston University School of Medicine and the American Academy of Pediatrics. Dr. Bagley reported receiving grants from the National Institute on Drug Abuse/National Institutes of Health and Centers for Disease Control and Prevention and being a paid speaker for the Opioid Response Network. Dr. Korthuis reported receiving grants from the National Institute on Drug Abuse/National Institutes of Health. Dr Englander reported receiving grants from the National Institute on Drug Abuse/National Institutes of Health (UG1DA015815). No other disclosures were reported.
Figures
Figure.. Inclusion of Facilities in a Study…
Figure.. Inclusion of Facilities in a Study Assessing Adolescent Residential Treatment Facilities, 2022
Figure.. Inclusion of Facilities in a Study Assessing Adolescent Residential Treatment Facilities, 2022
The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 focused update. J Addict Med. 2020;14(2S suppl 1):1-91. doi:10.1097/ADM.0000000000000633
-
DOI
-
PubMed
Society for Adolescent Health and Medicine . Medication for adolescents and young adults with opioid use disorder. J Adolesc Health. 2021;68(3):632-636. doi:10.1016/j.jadohealth.2020.12.129
-
DOI
-
PMC
-
PubMed
Hadland SE, Wharam JF, Schuster MA, Zhang F, Samet JH, Larochelle MR. Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014. JAMA Pediatr. 2017;171(8):747-755. doi:10.1001/jamapediatrics.2017.0745
-
DOI
-
PMC
-
PubMed
Beetham T, Saloner B, Gaye M, Wakeman SE, Frank RG, Barnett ML. Therapies offered at residential addiction treatment programs in the United States. JAMA. 2020;324(8):804-806. doi:10.1001/jama.2020.8969
-
DOI
-
PMC
-
PubMed